Quick Answer
Instil Bio, Inc. reported Operating Income Loss of -$78.58 million for the year ending 2025.
- Instil Bio, Inc. showed a decrease of -6.9% in Operating Income Loss from 2024 to 2025.
- This data is from Instil Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$3.86 million | Q2 2020: -$4.59 million | Q3 2020: -$7.71 million | Q1 2021: -$23.40 million | Q2 2021: -$35.38 million | Q3 2021: -$43.02 million | Q1 2022: -$54.29 million | Q2 2022: -$58.72 million | Q3 2022: -$56.65 million | Q1 2023: -$58.45 million | Q2 2023: -$20.99 million | Q3 2023: -$66.72 million | Q1 2024: -$23.96 million | Q2 2024: -$14.14 million | Q3 2024: -$23.63 million | Q1 2025: -$30.56 million | Q2 2025: -$23.44 million | Q3 2025: -$15.02 million.
- Over the full 6 years of available data (2020 to 2025), Instil Bio, Inc.'s Operating Income Loss has declined by 133.6%.
- Historical annual values: Fiscal year 2025: -$78.58 million | Fiscal year 2024: -$73.54 million | Fiscal year 2023: -$159.17 million | Fiscal year 2022: -$226.46 million | Fiscal year 2021: -$155.56 million | Fiscal year 2020: -$33.64 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: